Navitoclax, an experimental cancer medication approved nowhere, is studied for clearing worn-out cells that build up with age. In animals this restored stem cell function, reversed lung scarring, refreshed skin and protected joints, but also caused bone loss and less stable artery plaque. Human evidence comes only from cancer treatment; no human longevity study or established dose exists, and bleeding risk caps the usable dose. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Platelet count | 150–400 × 10⁹/L; escalation requires ≥75 × 10⁹/L | Tracks the dose-limiting harm |
| Absolute neutrophil count | ≥2.0 × 10⁹/L | Flags infection risk before fever appears |
| Haemoglobin | 13.5–15.0 g/dL (men); 12.5–14.0 g/dL (women) | Detects anaemia, which is bidirectional on this drug |
| Absolute lymphocyte count | 1.5–3.0 × 10⁹/L | Captures T-cell depletion driving infection risk |
| Alanine aminotransferase (ALT) | 10–26 U/L (men); 8–22 U/L (women) | Detects the reversible liver enzyme rise seen in early trials |
| Total bilirubin | 0.3–1.0 mg/dL | Confirms liver handling capacity for a hepatically cleared drug |
| High-sensitivity C-reactive protein | <1.0 mg/L | Proxy for the inflammatory output of senescent cells |
| Interleukin-6 | <2.0 pg/mL | Most consistently senescence-linked inflammatory signal |
| Estimated glomerular filtration rate | >90 mL/min/1.73 m² | Establishes eligibility; no kidney data exist for this drug |
| Senescent-cell burden (p16INK4a expression) | No established target exists; track change from the individual's own baseline | The only direct readout of whether senolysis occurred |
Cadence: Full blood count weekly through week 8, then monthly to month 6, then every 3 to 6 months; liver enzymes at each dose escalation and every 4 weeks once stable